158 related articles for article (PubMed ID: 16052908)
1. Adenovirus-mediated CTLA4Ig or CD40Ig gene transfer delays pancreatic islet rejection in a rat-to-mouse xenotransplantation model after systemic but not local expression.
Potiron N; Chagneau C; Boeffard F; Soulillou JP; Anegon I; Le Mauff B
Cell Transplant; 2005; 14(5):263-75. PubMed ID: 16052908
[TBL] [Abstract][Full Text] [Related]
2. CTLA4Ig adenoviral gene transfer induces long-term islet rat allograft survival, without tolerance, after systemic but not local intragraft expression.
Laumonier T; Potiron N; Boeffard F; Chagneau C; Brouard S; Guillot C; Soulillou JP; Anegon I; Le Mauff B
Hum Gene Ther; 2003 Apr; 14(6):561-75. PubMed ID: 12718766
[TBL] [Abstract][Full Text] [Related]
3. Prolonged xenograft survival of islets infected with small doses of adenovirus expressing CTLA4Ig.
Feng S; Quickel RR; Hollister-Lock J; McLeod M; Bonner-Weir S; Mulligan RC; Weir GC
Transplantation; 1999 Jun; 67(12):1607-13. PubMed ID: 10401769
[TBL] [Abstract][Full Text] [Related]
4. Co-stimulatory molecules in islet xenotransplantation: CTLA4Ig treatment in CD40 ligand-deficient mice.
Benda B; Ljunggren HG; Peach R; Sandberg JO; Korsgren O
Cell Transplant; 2002; 11(7):715-20. PubMed ID: 12518898
[TBL] [Abstract][Full Text] [Related]
5. Combined gene therapy with adenovirus vectors containing CTLA4Ig and CD40Ig prolongs survival of composite tissue allografts in rat model.
Kanaya K; Tsuchida Y; Inobe M; Murakami M; Hirose T; Kon S; Kawaguchi S; Wada T; Yamashita T; Ishii S; Uede T
Transplantation; 2003 Feb; 75(3):275-81. PubMed ID: 12589145
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy with nondepleting anti-CD4 monoclonal antibodies but not CD28 antagonists protects islet graft in spontaneously diabetic nod mice from autoimmune destruction and allogeneic and xenogeneic graft rejection.
Guo Z; Wu T; Kirchhof N; Mital D; Williams JW; Azuma M; Sutherland DE; Hering BJ
Transplantation; 2001 Jun; 71(11):1656-65. PubMed ID: 11435979
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulation of pancreatic islet allografts in mice with CTLA4Ig secreting muscle cells.
Chahine AA; Yu M; McKernan MM; Stoeckert C; Lau HT
Transplantation; 1995 May; 59(9):1313-8. PubMed ID: 7762068
[TBL] [Abstract][Full Text] [Related]
8. Prevention of autoimmune recurrence and rejection by adenovirus-mediated CTLA4Ig gene transfer to the pancreatic graft in BB rat.
Uchikoshi F; Yang ZD; Rostami S; Yokoi Y; Capocci P; Barker CF; Naji A
Diabetes; 1999 Mar; 48(3):652-7. PubMed ID: 10078573
[TBL] [Abstract][Full Text] [Related]
9. Proliferative and cytokine responses in CTLA4-Ig-treated diabetic NOD mice transplanted with microencapsulated neonatal porcine ICCs.
Safley SA; Kapp JA; Weber CJ
Cell Transplant; 2002; 11(7):695-705. PubMed ID: 12518896
[TBL] [Abstract][Full Text] [Related]
10. Blockade of the CD28 and CD40 pathways result in the acceptance of pig and rat islet xenografts but not rat cardiac grafts in mice.
Lehnert AM; Mottram PL; Han W; Walters SN; Patel AT; Hawthorne WJ; Cowan PJ; d'Apice AJ; O'Connell PJ
Transpl Immunol; 2001 Oct; 9(1):51-6. PubMed ID: 11680572
[TBL] [Abstract][Full Text] [Related]
11. Cardiac allograft tolerance induced by intra-arterial infusion of recombinant adenoviral CTLA4Ig.
Yang Z; Rostami S; Koeberlein B; Barker CF; Naji A
Transplantation; 1999 Jun; 67(12):1517-23. PubMed ID: 10401757
[TBL] [Abstract][Full Text] [Related]
12. Tolerance to cardiac allografts via local and systemic mechanisms after adenovirus-mediated CTLA4Ig expression.
Guillot C; Mathieu P; Coathalem H; Le Mauff B; Castro MG; Tesson L; Usal C; Laumonier T; Brouard S; Soulillou JP; Lowenstein PR; Cuturi MC; Anegon I
J Immunol; 2000 May; 164(10):5258-68. PubMed ID: 10799887
[TBL] [Abstract][Full Text] [Related]
13. Regulatory T cells maintain peripheral tolerance to islet allografts induced by intrathymic injection of MHC class I allopeptides.
Saborio DV; Chowdhury NC; Jin MX; Chandraker A; Sayegh MH; Oluwole SF
Cell Transplant; 1999; 8(4):375-81. PubMed ID: 10478717
[TBL] [Abstract][Full Text] [Related]
14. Pancreatic islet xenograft survival in mice is extended by a combination of alpha-1-antitrypsin and single-dose anti-CD4/CD8 therapy.
Ashkenazi E; Baranovski BM; Shahaf G; Lewis EC
PLoS One; 2013; 8(5):e63625. PubMed ID: 23717456
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-4 or interleukin-10 expressed from adenovirus-transduced syngeneic islet grafts fails to prevent beta cell destruction in diabetic NOD mice.
Smith DK; Korbutt GS; Suarez-Pinzon WL; Kao D; Rajotte RV; Elliott JF
Transplantation; 1997 Oct; 64(7):1040-9. PubMed ID: 9381527
[TBL] [Abstract][Full Text] [Related]
16. Effect of transplantation site and culture pretreatment on islet xenograft survival (rat to mouse) in experimental diabetes without immunosuppression of the host.
Jaeger C; Wöhrle M; Bretzel RG; Federlin K
Acta Diabetol; 1994 Dec; 31(4):193-7. PubMed ID: 7888689
[TBL] [Abstract][Full Text] [Related]
17. Secretion of CTLA4Ig by an SV40 T antigen-transformed islet cell line inhibits graft rejection against the neoantigen.
Lew AM; Brady JL; Silva A; Coligan JE; Georgiou HM
Transplantation; 1996 Jul; 62(1):83-9. PubMed ID: 8693551
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of transplant rejection by pretreatment of xenogeneic pancreatic islet cells with anti-ICAM-1 antibodies.
Zeng Y; Gage A; Montag A; Rothlein R; Thistlethwaite JR; Bluestone JA
Transplantation; 1994 Sep; 58(6):681-9. PubMed ID: 7940687
[TBL] [Abstract][Full Text] [Related]
19. Production of marked prolongation of islet xenograft survival (rat to mouse) by local release of mouse and rat antilymphocyte sera at transplant site.
Aebischer P; Lacy PE; Gerasimidi-Vazeou A; Hauptfeld V
Diabetes; 1991 Apr; 40(4):482-5. PubMed ID: 2010049
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor-alpha prevents rejection of islet xenografts (rat to mouse).
Gerasimidi A; Sheehan KC; Schreiber RD; Lacy PE
Diabetes; 1993 May; 42(5):651-7. PubMed ID: 8482422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
